Metabolic flare phenomenon mimicking disease progression on 18Flouride– Fluorodeoxyglucose PET/CT scan in breast cancer treated with paclitaxel-based chemotherapy

Document Type : Case report

Authors

Department of nuclear medicine SGPGIMS, India

Abstract

18F-fluorodeoxyglucose Positron emission tomography (18F-FDG PET/CT ) is now being used as a single modality for metastatic workup and response evaluation in breast cancer. An increase in metabolic activity indicates disease progression; however, metabolic flare should be kept in mind. Metabolic flare is a well-documented phenomenon reported in metastatic breast and prostate cancer. Despite a favorable response to therapy, there is a paradoxical increase in radiopharmaceutical uptake. The flare phenomenon with various chemotherapeutic and hormonal agents is well acknowledged in bone scintigraphy. However, very few cases have been documented on PET/CT. Increased uptake may be noted after treatment is instituted. The increased osteoblastic activity is associated with the healing response of bone tumors. We report a case of treated breast cancer. She presented with metastatic recurrence after four years of initial management. The patient was started on paclitaxel chemotherapy. Serial 18F- FDG PET/CT demonstrated metabolic flare and complete metabolic response.

Keywords

Main Subjects

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209–49.
  2. Majeed W, Aslam B, Javed I, Khaliq T, Muhammad F, Ali A, et al. Breast cancer: major risk factors and recent developments in treatment. Asian Pac J Cancer Prev APJCP. 2014; 15(8):3353–8.
  3. Drukteinis JS, Mooney BP, Flowers CI, Gatenby RA. Beyond mammography: new frontiers in breast cancer screening. Am J Med. 2013; 126(6):472–9.
  4. Wu Q, Li J, Zhu S, Wu J, Chen C, Liu Q, et al. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study. Oncotarget. 2017; 8(17): 27990–6.
  5. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019; 321(3): 288–300.
  6. Schuster DM. Clinical Utility of PET scanning in Breast Cancer Management. Am J Hematol Oncol [Internet].2015 Jun 19 [cited 2020 Apr 20]; 11 (6). Available from: https://www.gotoper.com/publications/ajho/2015/2015june/clinical-utility-of-pet-scanning-in-breast-cancer-management.
  7. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2001; 19 (11):2797–803.
  8. Tu DG, Yao WJ, Chang TW, Chiu NT, Chen YH. Flare phenomenon in positron emission tomography in a case of breast cancer-a pitfall of positron emission tomography imaging interpretation. Clin Imaging. 2009; 33(6):468–70.
  9. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747–52.
  10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2): 228–47.
  11. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. J Nucl Med. 2009; 50(Suppl 1):122S-150S.
  12. Gennari A, Donati S, Salvadori B, Giorgetti A, Salvadori PA, Sorace O, et al. Role of 2-[18F]-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) in the Early Assessment of Response to Chemotherapy in Metastatic Breast Cancer Patients. Clin Breast Cancer. 2000; 1(2):156–61.
  13. Tateishi U, Gámez C, Dawood S, Yeung HWD, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. 2008 Apr [cited 2022 Jul 8]; Available from: http:// diposit.ub.edu/dspace/handle/2445/132864.
  14. Schneider JA, Divgi CR, Scott AM, Macapinlac HA, Seidman AD, Goldsmith SJ, et al. flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med Off Publ Soc Nucl Med. 1994; 35(11):1748–52.
  15. D’Amico A, Kowalska T. Paradoxal metabolic flare detected by 18F-fluorodeoxyglucose positron emission tomography in a patient with metastatic breast cancer treated with aromatase inhibitor and biphosphonate. Indian J Nucl Med IJNM off J Soc Nucl Med India. 2014; 29(1):34–7.
  16. Balasubramanian Harisankar CN, Preethi R, John J. Metabolic flare phenomenon on 18 fluoride-fluorodeoxy glucose positron emission tomography-computed tomography scans in a patient with bilateral breast cancer treated with second-line chemotherapy and bevacizumab. Indian J Nucl Med IJNM off J Soc Nucl Med India. 2015; 30(2):145–7.
  17. Reddel RR, Sutherland RL. Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare. Eur J Cancer Clin Oncol. 1984; 20(11):1419–24.
  18. Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H. Up-regulation of estrogen receptor by tamoxifen in human breast cancer. Cancer. 1993; 71(4):1266–72.
  19. Coleman RE, Mashiter G, Whitaker KB, Moss DW, Rubens RD, Fogelman I. Bone scan flare predicts successful systemic therapy for bone metastases. Journal of nuclear medicine. 1988 1; 29(8):1354-9.
  20. Vogel CL, Schoenfelder J, Shemano I, Hayes DF, Gams RA. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 1995; 13(5):1123–8.
  21. Van Schelven WD, Pauwels EKJ. The flare phenomenon: far from fair and square. Eur J Nucl Med. 1994; 21(5):377–80.
Asia Oceania Journal of Nuclear Medicine and Biology
Volume 11, Issue 2
June 2023
Pages 175-180

Files

Share

How to cite

Statistics